Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder-Reference-Cited by-同舟云学术

Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder

Published:2024-06-22 Issue:6 Volume:47 Page:1204-1208
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Doi Kinuka¹,Sogawa Rintaro¹,Eguchi Yuko²,Matsuo Muneaki³,Shimanoe Chisato¹

Affiliation:

1. Department of Pharmacy, Saga University Hospital

2. Eguchi Hospital

3. Department of Pediatrics, Faculty of Medicine, Saga University

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/6/47_b24-00147/_pdf

Reference21 articles.

1. 1) Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 128, 1007–1022 (2011).

2. 2) Felt BT, Biermann B, Christner JG, Kochhar P, Harrison RV. Diagnosis and management of ADHD in children. Am. Fam. Physician, 90, 456–464 (2014).

3. 3) Ando M, Momo K, Hida N, Yamazaki T, Taki I, Nagai T, Yoshio T, Kurosawa M. Assessment of diagnosis timing of attention-deficit/hyperactivity disorder in working-age workers with psychiatric diseases using large claims data. Biol. Pharm. Bull., 46, 1211–1216 (2023).

4. 4) Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol. Ther., 230, 107940 (2022).

5. 5) Cruz MP. Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alpha(2A)-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. P&T, 35, 448–451 (2010).